Skip to main content
. 2022 Dec 6;13(2):298–311. doi: 10.1158/2159-8290.CD-22-1066

Figure 2.

Figure 2. KRASG12D inhibition alters the tumor immune microenvironment. A–D, Flow cytometry of indicated cell subsets from 6419c5 (subcutaneous) tumors after 5 doses over 60 hours of vehicle (n = 6) or MRTX1133 (n = 6). Ratio of M1-like (MHC-II+) to M2-like (CD206+) macrophages in 6419c5 (subcutaneous) tumors after 5 doses of vehicle or MRTX1133 (D, middle). M1/M2 ratio plotted as the frequency of total macrophages (D, right). P values were determined by an unpaired Student t test. Error bars, SD. E, Representative coimmunofluorescent images of F4/80, GFP, and DAPI in vehicle- and MRTX1133-treated tumors (6419c5, subcutaneous, 60 hours). Scale bars, 100 μm. Objective, 20×. F, Quantitation of macrophages (F4/80+) as percent area per HPF in vehicle- (n = 3) and MRTX1133-treated tumors (n = 3). At least 3 fields of view were averaged per tumor. P values were determined by an unpaired Student t test. Error bars, SD. G, Flow cytometry of T-cell subsets from 6419c5 (subcutaneous) tumors after 5 doses over 60 hours of vehicle (n = 5) or MRTX1133 (n = 5). P values were determined by an unpaired Student t test. Error bars, indicate SD. Results are representative of n = 3 independent experiments. H, Flow cytometry of T-cell subsets from 6419c5 (subcutaneous) tumors after 5 doses over 60 hours of vehicle (n = 15) or MRTX1133 (n = 16). Mean fluorescence intensity (MFI) of Ki-67 and GZMB on CD8+ T cells. P values were determined by an unpaired Student t test. Error bars, SD. I, Flow cytometry of T-cell subsets from 6419c5 (subcutaneous) TDLNs after 5 doses over 60 hours of vehicle (n = 16) or MRTX1133 (n = 16). P values were determined by an unpaired Student t test. Error bars, SD.

KRASG12D inhibition alters the tumor immune microenvironment. A–D, Flow cytometry of indicated cell subsets from 6419c5 (subcutaneous) tumors after 5 doses over 60 hours of vehicle (n = 6) or MRTX1133 (n = 6). Ratio of M1-like (MHC-II+) to M2-like (CD206+) macrophages in 6419c5 (subcutaneous) tumors after 5 doses of vehicle or MRTX1133 (D, middle). M1/M2 ratio plotted as the frequency (freq.) of total macrophages (D, right). P values were determined by an unpaired Student t test. Error bars, SD. MFI, mean fluorescence intensity; moMDSC, monocytic myeloid-derived suppressor cell. E, Representative coimmunofluorescent images of F4/80, GFP, and DAPI in vehicle- and MRTX1133-treated tumors (6419c5, subcutaneous, 60 hours). Scale bars, 100 μm. Objective, 20×. F, Quantitation of macrophages (F4/80+) as percent area per high-power field in vehicle-treated (n = 3) and MRTX1133-treated (n = 3) tumors. At least 3 fields of view were averaged per tumor. P values were determined by an unpaired Student t test. Error bars, SD. G, Flow cytometry of T-cell subsets from 6419c5 (subcutaneous) tumors after 5 doses over 60 hours of vehicle (n = 5) or MRTX1133 (n = 5). P values were determined by an unpaired Student t test. Error bars, indicate SD. Results are representative of 3 independent experiments. H, Flow cytometry of T-cell subsets from 6419c5 (subcutaneous) tumors after 5 doses over 60 hours of vehicle (n = 15) or MRTX1133 (n = 16). MFI of Ki-67 and GZMB on CD8+ T cells. P values were determined by an unpaired Student t test. Error bars, SD. I, Flow cytometry of T-cell subsets from 6419c5 (subcutaneous) TDLNs after 5 doses over 60 hours of vehicle (n = 16) or MRTX1133 (n = 16). P values were determined by an unpaired Student t test. Error bars, SD.